HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dawson, K. G. Articles by Kahler, K. H. Search for Related Content PubMed PubMed Citation Articles by Dawson, K. G. Articles by Kahler, K. H. Social Bookmarking                What's this?

The Economic Cost of Diabetes in Canada, 1998

¹ Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
² Merck, Whitehouse Station, New Jersey
³ Department of Medicine, McMaster University, Hamilton, Ontario, Canada
⁴ Department of Community Health Services, University of Manitoba, Winnipeg, Manitoba, Canada

OBJECTIVE—In Canada, diabetes poses a significant health problem, and current estimates of its economic burden have not incorporated the total cost of the disease. The objective of this study was to quantify the direct medical- and mortality-related productivity cost of diabetes in Canada for 1998.

RESEARCH DESIGN AND METHODS—Direct medical costs included hospital services, physician services, and medicines consumed by people with diabetes. These costs were based on a top-down costing methodology that allocated 1998 total medical expenditures to diabetes. The prevalence of diagnosed and undiagnosed diabetes and the relative risk of complications in people with diabetes were used to estimate the proportion of medical services that were consumed by people with diabetes. Mortality-related productivity losses were calculated using the human capital approach.

RESULTS—After varying the assumptions in a sensitivity analysis, the total economic burden (in U.S. dollars) of diabetes and its chronic complications in Canada for 1998 was likely to be between $4.76 and $5.23 billion. In those people just with diagnosed diabetes, the direct medical costs associated with diabetes care, before considering any complications, were $573 million. Of the costs associated with the complications of diabetes, cardiovascular disease was by far the greatest, at $637 million.

CONCLUSIONS—Cardiovascular disease was the major contributor to the direct costs of diabetes. The preventive management of diabetes should receive priority attention, and the prevention of cardiovascular disease in the patient with diabetes should become an imperative.

Abbreviations: ADA, American Diabetes Association • MDC, major diagnostic category

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. R. Shah Utilization of physician services for diabetic patients from ethnic minorities J. Public Health Med., September 1, 2008; 30(3): 327 - 331. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				R. Azziz, C. Marin, L. Hoq, E. Badamgarav, and P. Song Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4650 - 4658. [Abstract] [Full Text] [PDF]

				J. Oliva, F. Lobo, B. Molina, and S. Monereo Direct Health Care Costs of Diabetic Patients in Spain Diabetes Care, November 1, 2004; 27(11): 2616 - 2621. [Abstract] [Full Text] [PDF]

				S. L. Bowker, C. G. Mitchell, S. R. Majumdar, E. L. Toth, and J. A. Johnson Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes Can. Med. Assoc. J., July 6, 2004; 171(1): 39 - 43. [Abstract] [Full Text] [PDF]

				M. Heisler Glycemic self-monitoring and insurance coverage Can. Med. Assoc. J., July 6, 2004; 171(1): 48 - 49. [Full Text] [PDF]

				A. Arredondo and A. Zuniga Economic Consequences of Epidemiological Changes in Diabetes in Middle-Income Countries: The Mexican case Diabetes Care, January 1, 2004; 27(1): 104 - 109. [Abstract] [Full Text] [PDF]

				S. H. Simpson, P. Corabian, P. Jacobs, and J. A. Johnson The cost of major comorbidity in people with diabetes mellitus Can. Med. Assoc. J., June 24, 2003; 168(13): 1661 - 1667. [Abstract] [Full Text] [PDF]